Literature DB >> 29029109

Early diagnosis of acute coronary syndrome.

Hugo Katus1, André Ziegler2, Okan Ekinci3,4, Evangelos Giannitsis1, Wendy Gattis Stough5, Stephan Achenbach6, Stefan Blankenberg7, Martina Brueckmann8,9, Paul Collinson10,11, Dorin Comaniciu3, Filippo Crea12, Wilfried Dinh13,14, Grégory Ducrocq15, Frank A Flachskampf16, Keith A A Fox17, Matthias G Friedrich18,19, Kathy A Hebert20, Anders Himmelmann21, Mark Hlatky22, Dominik Lautsch23, Bertil Lindahl16, Daniel Lindholm24, Nicholas L Mills25, Giorgio Minotti26, Martin Möckel27, Torbjørn Omland28, Véronique Semjonow29.   

Abstract

The diagnostic evaluation of acute chest pain has been augmented in recent years by advances in the sensitivity and precision of cardiac troponin assays, new biomarkers, improvements in imaging modalities, and release of new clinical decision algorithms. This progress has enabled physicians to diagnose or rule-out acute myocardial infarction earlier after the initial patient presentation, usually in emergency department settings, which may facilitate prompt initiation of evidence-based treatments, investigation of alternative diagnoses for chest pain, or discharge, and permit better utilization of healthcare resources. A non-trivial proportion of patients fall in an indeterminate category according to rule-out algorithms, and minimal evidence-based guidance exists for the optimal evaluation, monitoring, and treatment of these patients. The Cardiovascular Round Table of the ESC proposes approaches for the optimal application of early strategies in clinical practice to improve patient care following the review of recent advances in the early diagnosis of acute coronary syndrome. The following specific 'indeterminate' patient categories were considered: (i) patients with symptoms and high-sensitivity cardiac troponin <99th percentile; (ii) patients with symptoms and high-sensitivity troponin <99th percentile but above the limit of detection; (iii) patients with symptoms and high-sensitivity troponin >99th percentile but without dynamic change; and (iv) patients with symptoms and high-sensitivity troponin >99th percentile and dynamic change but without coronary plaque rupture/erosion/dissection. Definitive evidence is currently lacking to manage these patients whose early diagnosis is 'indeterminate' and these areas of uncertainty should be assigned a high priority for research. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2017. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Acute coronary syndrome; Troponin

Mesh:

Substances:

Year:  2017        PMID: 29029109     DOI: 10.1093/eurheartj/ehx492

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  13 in total

Review 1.  Artificial Intelligence in Cardiovascular Imaging: JACC State-of-the-Art Review.

Authors:  Damini Dey; Piotr J Slomka; Paul Leeson; Dorin Comaniciu; Sirish Shrestha; Partho P Sengupta; Thomas H Marwick
Journal:  J Am Coll Cardiol       Date:  2019-03-26       Impact factor: 24.094

Review 2.  Imaging in experimental models of diabetes.

Authors:  Andrea Coppola; Giada Zorzetto; Filippo Piacentino; Valeria Bettoni; Ida Pastore; Paolo Marra; Laura Perani; Antonio Esposito; Francesco De Cobelli; Giulio Carcano; Federico Fontana; Paolo Fiorina; Massimo Venturini
Journal:  Acta Diabetol       Date:  2021-11-15       Impact factor: 4.280

Review 3.  German contribution to development and innovations in the management of acute myocardial infarction and cardiogenic shock.

Authors:  Hans-Josef Feistritzer; Steffen Desch; Suzanne de Waha; Alexander Jobs; Uwe Zeymer; Holger Thiele
Journal:  Clin Res Cardiol       Date:  2018-05-16       Impact factor: 5.460

4.  Association between neutrophil-lymphocyte ratio and arterial stiffness in patients with acute coronary syndrome.

Authors:  Yanyan Li; Xiaofang Chen; Lingzhi Huang; Jinyang Lu
Journal:  Biosci Rep       Date:  2019-05-03       Impact factor: 3.840

5.  Myoglobin for Detection of High-Risk Patients with Acute Myocarditis.

Authors:  Jan Kottwitz; Katelyn A Bruno; Jan Berg; Gary R Salomon; DeLisa Fairweather; Mawahib Elhassan; Nora Baltensperger; Christine K Kissel; Marina Lovrinovic; Andrea Baltensweiler; Christian Schmied; Christian Templin; Joao A C Lima; Ulf Landmesser; Thomas F Lüscher; Robert Manka; Bettina Heidecker
Journal:  J Cardiovasc Transl Res       Date:  2020-01-31       Impact factor: 3.216

6.  Serum Metabonomic Study of Patients With Acute Coronary Syndrome Using Ultra-Performance Liquid Chromatography Orbitrap Mass Spectrometer.

Authors:  Lei Song; Zhongxiao Zhang; Zhaohui Qiu; Tingbo Jiang
Journal:  Front Cardiovasc Med       Date:  2021-02-26

7.  Therapeutic Efficacy and Safety of Safflower Injection in the Treatment of Acute Coronary Syndrome.

Authors:  Qiang Lu; Jiamin Xu; Qian Li; Wenzhen Wu; Yuling Wu; Jianhui Xie; Xiaobo Yang
Journal:  Evid Based Complement Alternat Med       Date:  2021-03-16       Impact factor: 2.629

8.  Absolute Change in High-Sensitivity Cardiac Troponin I at Three Hours After Presentation is Useful for Diagnosing Acute Myocardial Infarction in the Emergency Department.

Authors:  Jong Won Kim; Hanah Kim; Yeo-Min Yun; Kyeong Ryong Lee; Hyun Joong Kim
Journal:  Ann Lab Med       Date:  2020-06-17       Impact factor: 3.464

9.  Platelet Carcinoembryonic Antigen Cell Adhesion Molecule 5 (CEACAM5) as a Possible Novel Diagnostic Tool for Evaluation of Acute Coronary Syndrome.

Authors:  Wen Wan; Yujia Ye; Huawei Wang; Longjun Li; Yajuan Gu; Lai Yang; Lihong Yang; Han Liu; Chao Meng; Deng Li; Zhe Wang; Zhaohui Meng
Journal:  Med Sci Monit       Date:  2019-12-22

10.  High-Sensitivity Cardiac Troponin I and Clinical Risk Scores in Patients With Suspected Acute Coronary Syndrome.

Authors:  Andrew R Chapman; Kerrick Hesse; Jack Andrews; Kuan Ken Lee; Atul Anand; Anoop S V Shah; Dennis Sandeman; Amy V Ferry; Jack Jameson; Simran Piya; Stacey Stewart; Lucy Marshall; Fiona E Strachan; Alasdair Gray; David E Newby; Nicholas L Mills
Journal:  Circulation       Date:  2018-10-16       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.